Literature DB >> 29880883

Amygdala levels of the GluA1 subunit of glutamate receptors and its phosphorylation state at serine 845 in the anterior hippocampus are biomarkers of ictal fear but not anxiety.

Rodrigo Bainy Leal1,2,3, Mark William Lopes1,2, Douglas Affonso Formolo1,3, Cristiane Ribeiro de Carvalho1,3, Alexandre Ademar Hoeller1,4, Alexandra Latini1,2, Daniel Santos Sousa1,4,5, Peter Wolf4,6, Rui Daniel Prediger1,3,7, Zuner Assis Bortolotto8, Marcelo Neves Linhares1,5,9,10, Kátia Lin1,4,6,9, Roger Walz11,12,13,14,15.   

Abstract

Fear is a conscious state caused by exposure to real or imagined threats that trigger stress responses that affect the body and brain, particularly limbic structures. A sub-group of patients with mesial temporal lobe epilepsy related to hippocampus sclerosis (MTLE-HS) have seizures with fear, which is called ictal fear (IF), due to epileptic activity within the brain defensive survival circuit structures. Synaptic transmission efficacy can be bi-directionally modified through potentiation (long-term potentiation (LTP)) or depression (long-term depression (LTD)) as well as the phosphorylation state of Ser831 and Ser845 sites at the GluA1 subunit of the glutamate AMPA receptors, which has been characterized as a critical event for this synaptic plasticity. In this study, GluA1 levels and the phosphorylation at Ser845 and Ser831 in the amygdala (AMY), anterior hippocampus (aHIP) and middle gyrus of temporal neocortex (CX) were determined with western blots and compared between MTLE-HS patients who were showing (n = 06) or not showing (n = 25) IF. Patients with IF had an 11% decrease of AMY levels of the GluA1 subunit (p = 0.05) and a 21.5% decrease of aHIP levels of P-GluA1-Ser845 (p = 0.009) compared to patients not showing IF. The observed associations were not related to imbalances in the distribution of other concomitant types of aura, demographic, clinical or neurosurgical variables. The lower levels of P-GluA1-Ser845 in the aHIP of patients with IF were not related to changes in the levels of the serine/threonine-protein phosphatase PP1-alpha catalytic subunit or protein kinase A activation. Taken together, the GluA1 subunit levels in AMY and P-GluA1-Ser845 levels in the aHIP show an overall accuracy of 89.3% (specificity 95.5% and sensitivity 66.7%) to predict the presence of IF. AMY levels of the GluA1 subunit and aHIP levels of P-GluA1-Ser845 were not associated with the psychiatric diagnosis and symptoms of patients. Taken together with previous findings in MTLE-HS patients with IF who were evaluated by stereotactic implanted depth electrodes, we speculate our findings are consistent with the hypothesis that AMY is not a centre of fear but together with other sub-cortical and cortical structures integrates the defensive circuit that detect and respond to threats. This is the first report to address neuroplasticity features in human limbic structures connected to the defensive survival circuits, which has implications for the comprehension of highly prevalent psychiatric disorders and symptoms.

Entities:  

Year:  2018        PMID: 29880883     DOI: 10.1038/s41380-018-0084-7

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  62 in total

Review 1.  Cellular prion protein: implications in seizures and epilepsy.

Authors:  Roger Walz; Rosa Maria R P S Castro; Tonicarlo R Velasco; Carlos G Carlotti; Américo C Sakamoto; Ricardo R Brentani; Vilma R Martins
Journal:  Cell Mol Neurobiol       Date:  2002-06       Impact factor: 5.046

Review 2.  Stress and the brain: individual variability and the inverted-U.

Authors:  Robert M Sapolsky
Journal:  Nat Neurosci       Date:  2015-10       Impact factor: 24.884

Review 3.  Using Neuroscience to Help Understand Fear and Anxiety: A Two-System Framework.

Authors:  Joseph E LeDoux; Daniel S Pine
Journal:  Am J Psychiatry       Date:  2016-09-09       Impact factor: 18.112

4.  Amygdala-hippocampus relationships in temporal lobe seizures: a phase-coherence study.

Authors:  J Gotman; V Levtova
Journal:  Epilepsy Res       Date:  1996-09       Impact factor: 3.045

5.  Predictors of meaningful improvement in quality of life after temporal lobe epilepsy surgery: A prospective study.

Authors:  Carla Pauli; Marcelo Liborio Schwarzbold; Alexandre Paim Diaz; Maria Emilia Rodrigues de Oliveira Thais; Charles Kondageski; Marcelo Neves Linhares; Ricardo Guarnieri; Bianca de Lemos Zingano; Juliana Ben; Jean Costa Nunes; Hans Joachim Markowitsch; Peter Wolf; Samuel Wiebe; Katia Lin; Roger Walz
Journal:  Epilepsia       Date:  2017-03-23       Impact factor: 5.864

6.  A randomized, controlled trial of surgery for temporal-lobe epilepsy.

Authors:  S Wiebe; W T Blume; J P Girvin; M Eliasziw
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

Review 7.  Defining epileptogenic networks: Contribution of SEEG and signal analysis.

Authors:  Fabrice Bartolomei; Stanislas Lagarde; Fabrice Wendling; Aileen McGonigal; Viktor Jirsa; Maxime Guye; Christian Bénar
Journal:  Epilepsia       Date:  2017-05-20       Impact factor: 5.864

Review 8.  Resective epilepsy surgery for drug-resistant focal epilepsy: a review.

Authors:  Barbara C Jobst; Gregory D Cascino
Journal:  JAMA       Date:  2015-01-20       Impact factor: 56.272

9.  Decline in word-finding: The objective cognitive finding most relevant to patients after mesial temporal lobe epilepsy surgery.

Authors:  Carla Pauli; Maria Emilia Rodrigues de Oliveira Thais; Ricardo Guarnieri; Marcelo Liborio Schwarzbold; Alexandre Paim Diaz; Juliana Ben; Marcelo Neves Linhares; Hans Joachim Markowitsch; Peter Wolf; Samuel Wiebe; Katia Lin; Roger Walz
Journal:  Epilepsy Behav       Date:  2017-09-01       Impact factor: 2.937

Review 10.  Models and mechanisms of experimental epilepsies.

Authors:  John G R Jefferys
Journal:  Epilepsia       Date:  2003       Impact factor: 5.864

View more
  7 in total

1.  A neuronal social trait space for first impressions in the human amygdala and hippocampus.

Authors:  Runnan Cao; Chujun Lin; Johnie Hodge; Xin Li; Alexander Todorov; Nicholas J Brandmeir; Shuo Wang
Journal:  Mol Psychiatry       Date:  2022-06-08       Impact factor: 15.992

2.  Correlation Between Ictal Signs and Anatomical Subgroups in Temporal Lobe Seizures: A Stereoelectroencephalography Study.

Authors:  Bo Zhang; Jing Wang; Mengyang Wang; Xiongfei Wang; Yuguang Guan; Zhao Liu; Yao Zhang; Changqing Liu; Meng Zhao; Pandeng Xie; Mingwang Zhu; Tianfu Li; Guoming Luan; Jian Zhou
Journal:  Front Neurol       Date:  2022-06-10       Impact factor: 4.086

3.  Occipital Lobe Epilepsy With Ictal Fear: Evidence From a Stereo-Electroencephalography (sEEG) Case.

Authors:  Jing Wang; Qian Wang; Mengyang Wang; Guoming Luan; Jian Zhou; Yuguang Guan; Zhaofen Yan
Journal:  Front Neurol       Date:  2018-08-07       Impact factor: 4.003

Review 4.  Neuroproteomics in Epilepsy: What Do We Know so Far?

Authors:  Amanda M do Canto; Amanda Donatti; Jaqueline C Geraldis; Alexandre B Godoi; Douglas C da Rosa; Iscia Lopes-Cendes
Journal:  Front Mol Neurosci       Date:  2021-01-07       Impact factor: 5.639

Review 5.  Multipronged Attack of Stem Cell Therapy in Treating the Neurological and Neuropsychiatric Symptoms of Epilepsy.

Authors:  Nadia Sadanandan; Madeline Saft; Bella Gonzales-Portillo; Cesar V Borlongan
Journal:  Front Pharmacol       Date:  2021-03-17       Impact factor: 5.810

Review 6.  Neuroplastin in Neuropsychiatric Diseases.

Authors:  Xiao Lin; Yi Liang; Rodrigo Herrera-Molina; Dirk Montag
Journal:  Genes (Basel)       Date:  2021-09-26       Impact factor: 4.096

7.  The ERK phosphorylation levels in the amygdala predict anxiety symptoms in humans and MEK/ERK inhibition dissociates innate and learned defensive behaviors in rats.

Authors:  Cristiane Ribeiro de Carvalho; Mark William Lopes; Leandra C Constantino; Alexandre Ademar Hoeller; Hiago Murilo de Melo; Ricardo Guarnieri; Marcelo Neves Linhares; Zuner Assis Bortolotto; Rui Daniel Prediger; Alexandra Latini; Katia Lin; Julio Licinio; Rodrigo Bainy Leal; Roger Walz
Journal:  Mol Psychiatry       Date:  2021-07-27       Impact factor: 15.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.